Cancer Chemotherapy and Pharmacology

, Volume 56, Issue 4, pp 436–446 | Cite as

Antiangiogenic and antitumoral properties of a polysaccharide isolated from the seaweed Sargassum stenophyllum

  • Paulo Fernando Dias
  • Jarbas Mota SiqueiraJr
  • Luiz Felipe Vendruscolo
  • Teresinha de Jesus Neiva
  • Antônio Ricardo Gagliardi
  • Marcelo Maraschin
  • Rosa Maria Ribeiro-do-ValleEmail author
Original Article


The potential antiangiogenic and antitumoral properties of SargA, a polysaccharide extracted from the brown marine alga Sargassum stenophyllum, were studied in assays carried out in chick embryos and mice. Gelfoam plugs containing SargA (2–1500 μg/plug) implanted in vivo into fertilized 6-day-old chicken eggs induced dose-related antiangiogenic activity in the chorioallantoic membrane (CAM). By day 8, the highest dose of SargA alone decreased the vessel number in the CAM by 64%, but coadministered with hydrocortisone (156 μg/plug, which alone caused 30% inhibition) failed to potentiate its antiangiogenic effect. Combined with basic fibroblast growth factor (50 ng/plug), SargA (1500 μg/plug) abolished angiogenesis stimulated by this factor in both chick embryo CAM and in subcutaneous (s.c.) Gelfoam plugs implanted in the dorsal skin of Swiss mice (measured as plug hemoglobin content). Repeated s.c. injections of SargA (1.5 or 150 μg per animal per day for 3 days) close to B16F10 melanoma cell tumors in the dorsal skin of mice markedly decreased tumor growth in a dose-related fashion (by 40% and 80% at 2 weeks after the first injection, respectively), without evident signs of toxicity. SargA caused graded inhibitions of migration and viability of cultured B16F10 cells and also displayed antithrombotic activity in human plasma (5 mg/ml increased thrombin time 2.5-fold relative to saline). Thus, SargA exhibits pronounced antiangiogenic as well as antitumoral properties. Although the latter action of SargA might be related to the inhibition of angiogenesis, the polysaccharide also exerts cytotoxic effects on tumor cells. Because of its chemical characteristics and polyanionic constituents, we postulate that the polysaccharide SargA might modulate the activity of heparin-binding angiogenic growth factors.


Polysaccharide Angiogenesis Antitumoral activity Sargassum stenophyllum Angiostatic activity 



The authors are indebted to Dr. M.L. Pessatti (Biochemistry and Molecular Biology Laboratory – CTTMar – UNIVALI, Itajaí – SC, Brazil) for providing the preprocessed biomass of the alga and Dr. A.G. Trentin (Laboratory of Cell and Molecular Neurobiology and Hematology– Cell Biology, Embryology and Genetics Department/CCB–UFSC) for providing the B16F10 cells. We are grateful to Dr. G.A. Rae (Pharmacology Department/CCB – UFSC) for his valuable assistance in scientific English as well as his invaluable collaboration in the development of this work.


  1. 1.
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedGoogle Scholar
  2. 2.
    Folkman J, Shing Y (1992) Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 313:355–364PubMedGoogle Scholar
  3. 3.
    Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442–447PubMedGoogle Scholar
  4. 4.
    Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenesis switch. Nat Rev Cancer 3:401–410CrossRefPubMedGoogle Scholar
  5. 5.
    Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364CrossRefPubMedGoogle Scholar
  6. 6.
    Folkman J (1995) Clinical applications of research on angiogenesis. N Engl J Med 333:1757–1763CrossRefPubMedGoogle Scholar
  7. 7.
    Gumbiner BM (1996) Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 84:345–357CrossRefPubMedGoogle Scholar
  8. 8.
    Kalluri R (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3:423–433CrossRefGoogle Scholar
  9. 9.
    Fachinger G, Deutsch U, Risau W (1999) Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene 18(43):5948–5953CrossRefPubMedGoogle Scholar
  10. 10.
    Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular specific growth factors and blood vessel formation. Nature 407:242–248CrossRefPubMedGoogle Scholar
  11. 11.
    Solimene ACC, Boscardin SB, Ferraz MGC, Chammas R (1999) Angiogenesis in solid tumors. SBOC 1:9–20Google Scholar
  12. 12.
    Chipperfield H, Kuldip SB, Simon MC, Nurcombe V (2002) Heparan sulfates isolated from adult neural progenitor cells can direct phenotypic maturation. Int J Dev Biol 46:661–670PubMedGoogle Scholar
  13. 13.
    Nugent MA, Iozzo RV (2000) Fibroblast growth factor-2. Int J Biochem Cell Biol 32:115–120CrossRefPubMedGoogle Scholar
  14. 14.
    Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31PubMedGoogle Scholar
  15. 15.
    Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D (1991) Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095–1104CrossRefPubMedGoogle Scholar
  16. 16.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257CrossRefPubMedGoogle Scholar
  17. 17.
    Koch AE (1998) Angiogenesis. Implications for rheumatoid arthritis. Arthritis Rheum 41(6):951–962Google Scholar
  18. 18.
    Jones N, Iljin K, Dumont DJ, Alitalo K (2001) Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2:257–267CrossRefPubMedGoogle Scholar
  19. 19.
    Crum R, Szabo S, Folkman J (1985) A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230:1375–1378PubMedGoogle Scholar
  20. 20.
    Hlatky L, Folkman F (2002) Clinical application antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 94:883–893PubMedGoogle Scholar
  21. 21.
    Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9(6):653–660CrossRefPubMedGoogle Scholar
  22. 22.
    Gagliardi AR, Hadd HE, Collins DC (1992) Inhibition of angiogenesis by suramin. Cancer Res 52:5073–5075PubMedGoogle Scholar
  23. 23.
    Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, Ribatti D, Rusnati M, Presta M (2001) Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 276(41):37900–37908PubMedGoogle Scholar
  24. 24.
    Cristofanilli M, Charnsangavej C, Ortobagyi GN (2002) Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov 1:415–426CrossRefPubMedGoogle Scholar
  25. 25.
    Koyanagi S, Tanigawa N, Nakagawa H, Soeda S, Shimeno H (2003) Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem Pharmacol 65:173–179CrossRefPubMedGoogle Scholar
  26. 26.
    Tan W, Lin L, Li M, Zhang YX, Tong Y, Xiao D, Ding J (2003) Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol 459(2):255–262CrossRefPubMedGoogle Scholar
  27. 27.
    Chen HH, Zhou HJ, Wang WQ, Wu GD (2004) Antimalarial dihydroartemisin also inhibits angiogenesis. Cancer Chemother Pharmacol 53:423–432CrossRefPubMedGoogle Scholar
  28. 28.
    Albano RM, Pavao MS, Mourao PA, Mulloy B (1990) Structural studies of a sulfated L-galactan from Styela plicata (Tunicate): analysis of the Smith-degraded polysaccharide. Carbohydr Res 208:163–174CrossRefPubMedGoogle Scholar
  29. 29.
    Berlinck RG, Ogawa CA, Almeida AM, Sanchez MA, Malpezzi EL, Costa LV, Hajdu E, de Freitas JC (1996) Chemical and pharmacological characterization of halitoxin from Amphimedon viridis (Porifera) from the southeastern Brazilian coast. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 115(2):155–163CrossRefPubMedGoogle Scholar
  30. 30.
    Mian AJ, Percival E (1973) Carbohydrates of the brown seaweeds Himanthalia lorea and Bifurcaria bifurcata. Structural studies of the “fucans”. Carbohydr Res 26:147–156Google Scholar
  31. 31.
    Abdel-Fattah A, Hussein MM-D, Salem HM (1974) Studies of the purification and some properties of sargassan, a sulphated heteropolysaccharide from Sargassum linifolium. Carbohydr Res 33:9–17CrossRefGoogle Scholar
  32. 32.
    Nishino T, Yokoyama G, Dobashi K, Fujihara M, Nagumo T (1989) Isolation, purification, and characterization of fucose-containing sulfated polysaccharides from the brown seaweed Ecklonia kurome and their blood-anticoagulant activities. Carbohydr Res 186:119–129CrossRefPubMedGoogle Scholar
  33. 33.
    Nishino T, Nagumo T (1992) Anticoagulant and antithrombin activities of oversulfated fucans. Carbohydr Res 229:355–362CrossRefPubMedGoogle Scholar
  34. 34.
    Mayer AMS, Paul VJ, Fenical W, Norris JN, Carvalho MS, Jacobs RS (1993) Phospholipase A2 inhibitors from marine algae. Hydrobiologia 260:521–529CrossRefGoogle Scholar
  35. 35.
    König GM, Wright AD (1995) Marine natural products research. Current directions and future potential. Planta Med 62:193–211Google Scholar
  36. 36.
    Noda H, Amano H, Arashima K, Hashimoto S, Nisizawa K (1989) Studies on the antitumor activity of marine algae. Nippon Suissan Gakkaishi 55(7):1259–1264Google Scholar
  37. 37.
    Duarte MER, Cardoso MA, Noseda M, Cerezo AS (2001) Structural studies on fucoidans from the brown seaweed Sargassum stenophyllum. Carbohydr Res 333:281–293CrossRefPubMedGoogle Scholar
  38. 38.
    Grumet M, Flaceus A, Margolis RRU (1993) Functional characterization of chondroitin sulphate proteoglycans of brain: interaction with neuron and neural cell adhesion molecules. J Cell Biol 120(3):815–824CrossRefPubMedGoogle Scholar
  39. 39.
    Katz BZ, Yamada KM (1997) Integrins in morphogenesis and signaling. Biochimie 79:467–476CrossRefPubMedGoogle Scholar
  40. 40.
    Selvendran RR, Stevens BJH, O’Neill MA (1985) Developments in the isolation and analysis of cell walls from edible plants. In: Brett CT, Hillman JR (eds) Biochemistry of the plant cell wall, Cambridge University Press, London, pp 39–78Google Scholar
  41. 41.
    Maraschin M, Carobrez SG, Persike D, Peixoto Ml, Ferreira AG, Ferracin R, Verpoorter R, Fontana JD (2000) Cell wall polysaccharides from Mandevilla velutina (Apocynaceae) cultured cells: extraction and chemical structure. Carbohydr Polym 41:55–60CrossRefGoogle Scholar
  42. 42.
    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedGoogle Scholar
  43. 43.
    Blumenkrantz N, Asboe-Hansen G (1973) New method for quantitative determination of uronic acids. Anal Biochem 54:484–489CrossRefPubMedGoogle Scholar
  44. 44.
    Gagliardi AR, Collins DC (1993) Inhibition of angiogenesis by antiestrogens. Cancer Res 53:533–535PubMedGoogle Scholar
  45. 45.
    Drabkin DL, Austin JH (1932) Spectrophotometric constants for common haemoglobin derivatives in human, dog, and rabbit blood. J Biol Chem 98:719–722Google Scholar
  46. 46.
    Lee YS, Yang HO, Shin KH, Choi HS, Jung SH, Hoon S, Kim YM, Oh DK, Linhardt RJ, Kim YS (2003) Suppression of tumor growth by a new glycosaminoglycan isolated from the African giant snail Achatina fulica. Eur J Pharmacol 465:191–198CrossRefPubMedGoogle Scholar
  47. 47.
    Ingber D, Fugita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348:555–557CrossRefPubMedGoogle Scholar
  48. 48.
    Burke RR (1973) A factor from a transformed cell line that affects cell migration. Proc Natl Acad Sci U S A 70:368–372Google Scholar
  49. 49.
    Igura K, Ohta T, Kuroda Y, Kaji K (2001) Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 171:11–16CrossRefPubMedGoogle Scholar
  50. 50.
    Carmichael J, Degraff WG, Gazdar AF, Minn JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942PubMedGoogle Scholar
  51. 51.
    Carlucci MJ, Pujol CA, Ciancia C, Noseda MD, Matulewicz MC, Damonte EB, Cerezo AS (1997) Antiherpetic and anticoagulant properties of carrageenans from the red seaweed Gigartina skottsbergii and their cyclized derivatives: correlation between structure and biological activity. Int J Biol Macromol 20:97–105CrossRefPubMedGoogle Scholar
  52. 52.
    Orr SF (1954) Infra-red spectroscopic studies of some polysaccharides. Biochem Biophys Acta 14:173–181CrossRefPubMedGoogle Scholar
  53. 53.
    Nguyen M, Shing Y, Folkman J (1994) Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res 47:31–40CrossRefPubMedGoogle Scholar
  54. 54.
    Jackson CJ, Giles I, Knop A, Nethery A, Schrieber L (1994) Sulfated polysaccharides are required for collagen-induced vascular tube formation. Exp Cell Res 215:294–302CrossRefPubMedGoogle Scholar
  55. 55.
    Gallagher JT (1994) Heparan sulphates as membrane receptors for the fibroblast growth factor. Eur J Clin Chem Clin Biochem 32:239–247PubMedGoogle Scholar
  56. 56.
    Dowd CJ, Cooney CL, Nugent MA (1999) Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding. J Biol Chem 274:5236–5244CrossRefPubMedGoogle Scholar
  57. 57.
    Miao H, Ornitz DM, Aingorn E, Ben-Sasson SA, Vlodavsky I (1997) Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. J Clin Invest 99:1565–1575Google Scholar
  58. 58.
    Mundhenke C, Meyer K, Drew S, Friedl A (2002) Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol 160:185–194PubMedGoogle Scholar
  59. 59.
    Matou S, Helly D, Chabut D, Bros A, Fischer A-M (2002) Effect of fucoidan on fibroblast growth factor-2-induced angiogenesis in vitro. Thromb Res 106:213–221CrossRefPubMedGoogle Scholar
  60. 60.
    Soeda S, Kosako T, Iwata K, Shimeno H (2000) Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: its possible mechanism of action. Biochim Biophys Acta 1497:127–134CrossRefPubMedGoogle Scholar
  61. 61.
    Coffey RJ Jr, Leof EB, Shipley GD, Moses HL (1987) Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 132:143–148CrossRefPubMedGoogle Scholar
  62. 62.
    Yayon A, Klagsbrun M (1990) Autocrine transformation by chimeric signal peptide–basic fibroblast growth factor: reversal by suramin. Proc Natl Acad Sci U S A 87:5346–5350PubMedGoogle Scholar
  63. 63.
    Pesenti E, Sol F, Mongelli N, Grandi M, Spreafico F (1992) Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Br J Cancer 66:367–374PubMedGoogle Scholar
  64. 64.
    Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA (1998) Solution structure of the heparin-binding domain vascular endothelial growth factor. Structure 6:637–648CrossRefPubMedGoogle Scholar
  65. 65.
    Princivalle M, de Agostini A (2002) Developmental roles of heparan sulfate proteoglycans a comparative review in Drosophila, mouse and human. Int J Dev Biol 46:267–278PubMedGoogle Scholar
  66. 66.
    Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP Jr (2001) Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 293:1663–1666CrossRefPubMedGoogle Scholar
  67. 67.
    Burg MA, Halfter W, Cole GJ (1995) Analysis of proteoglycan expression in developing chicken brain: characterization of a heparan sulfate proteoglycan that interacts with the neural cell adhesion molecule. J Neurosci Res 41:49–64CrossRefPubMedGoogle Scholar
  68. 68.
    Tobelem G (1990) Endothelial cell growth: biology and pharmacology in relation to angiogenesis. Blood Coagul Fibrinolysis 1:703–705PubMedGoogle Scholar
  69. 69.
    Takaku T, Kimura Y, Okuda H (2001) Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action. J Nutr 131:1409–1413PubMedGoogle Scholar
  70. 70.
    Nguyen NM, Leer JE, Pienta KJ (1993) Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res 13(6A):2143–2147PubMedGoogle Scholar
  71. 71.
    Zhang N, Deuel TF (1999) Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. Curr Opin Hematol 6:44–50CrossRefPubMedGoogle Scholar
  72. 72.
    Zeng C, Toole BP, Kinney SD, Kuo JW, Stamenkovic I (1998) Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 77(3):396–401CrossRefPubMedGoogle Scholar
  73. 73.
    Soeda S, Shibata Y, Shimeno H (1997) Inhibitory effect of oversulfated fucoidan on tube formation by human vascular endothelial cells. Biol Pharm Bull 20(11):1131–1135PubMedGoogle Scholar
  74. 74.
    Soeda S, Sakaguchi S, Shimeno H, Nagamatsu A (1992) Fibrinolytic and coagulant activities of highly sulfated fucoidan. Biochem Pharmacol 43(8):1853–1858CrossRefPubMedGoogle Scholar
  75. 75.
    Stein CA, La Rocca RV, Thomas R, McAtee N, Myers CE (1989) Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7:499–508Google Scholar
  76. 76.
    Gill JS, Windebank AJ (1998) Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ 5(10):876–883CrossRefPubMedGoogle Scholar
  77. 77.
    Myers C, Cooper M, Stein C, La Rocca R, McClellan MW, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J, Linehan MW (1992) Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881–889Google Scholar
  78. 78.
    Mauray S, Sternberg C, Theveniaux J, Millet J, Sinquin C, Tapon-Bretaudiere J, Fischer AM (1995) Venous antithrombotic and anticoagulant activities of a fucoidan fraction. Thromb Haemost 74:1280–1285PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Paulo Fernando Dias
    • 1
    • 2
  • Jarbas Mota SiqueiraJr
    • 1
  • Luiz Felipe Vendruscolo
    • 3
  • Teresinha de Jesus Neiva
    • 4
  • Antônio Ricardo Gagliardi
    • 5
    • 6
  • Marcelo Maraschin
    • 3
  • Rosa Maria Ribeiro-do-Valle
    • 1
    Email author
  1. 1.Departament of Pharmacology, Biological Sciences Center Block “D”Federal University of Santa CatarinaFlorianópolisBrazil
  2. 2.Department of Cell Biology, Embryology and Genetics – CCBFederal University of Santa CatarinaFlorianópolisBrazil
  3. 3.Plant Morphogenesis and Biochemistry Laboratory CCAFederal University of Santa CatarinaFlorianópolisBrazil
  4. 4.Department of Pharmaceutical Sciences CCSFederal University of Santa CatarinaFlorianópolisBrazil
  5. 5.Department of Physiology, Faculty of Medical Sciences of SantosCentro Universitário Lusíada – UNILUSSantos SPBrazil
  6. 6.Clinical Unit of Dyslipidemias, São Paulo Heart Institute Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo – HC-FMUSPSão PauloBrazil

Personalised recommendations